Is NCT06408298 recruiting in Lebanon, NH?

Yes, NCT06408298 is currently recruiting participants at its Lebanon, NH location. This resectable localized prostate cancer clinical trial is actively enrolling qualified participants.

Is participation in this Lebanon clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Resectable Localized Prostate Cancer Clinical Trial in Lebanon, NH

Q: How do I join the resectable localized prostate cancer clinical trial in Lebanon?

To join this clinical trial in Lebanon, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Resectable Localized Prostate Cancer Study in Lebanon

This is randomized, double blind, placebo controlled proof of principle (window of opportunity) study of oral hydroxychloroquine in patients with resectable localized prostate cancer. To determine the effects of hydroxychloroquine (HCQ) on markers of autophagy, such as p62, LC3-II and NBR-1 in prostate cancer tissue of patients with resectable localized prostate cancer who undergo radical prostatectomy. To monitor/observe the safety and tolerability of daily oral hydroxychloroquine in the pre and perioperative period in patients who undergo radical prostatectomy. To evaluate the concentration of hydroxychloroquine in normal and prostate tumor tissue and to correlate prostate tissue concentrations with the plasma concentrations in these patients. To perform tumor genomic analysis (for common somatic mutations) and to correlate the molecular response to HCQ and presence/absence of such mutations.

Sponsor: Lionel.D.Lewis, MD

Who Can Participate

Inclusion Criteria

All patients must have pathological confirmation of adenocarcinoma of the prostate Gleason score 6 (grade Group 1) or greater.

Patients must have resectable prostate cancer as defined by the AJCC (American Joint Committee on Cancer) TNM system and have planned radical prostatectomy.

Patients must have sufficient tissue from the initial diagnostic prostate biopsy, as determined by the study pathologist, to perform the required study analyses without exhausting the tissue required for clinical purposes

Age \>18 years

Adequate hematopoietic, hepatic and renal function documented prior to study entry to include: Hb. \> 10g/dL, WBC \> 3500/mm3, ANC \> 1500/mm3 and platelets \> 100,000/mm3; hepatic transaminases (AST or ALT) ≤ 2.0 times the upper limits of normal, total bilirubin ≤ 1.5 times the upper limits of normal, estimated creatinine clearance ≥ 60 mL/min or eGFR \> 60 mL/min/1.73 m2 and normal serum cations (K+/Mg2+/Ca2+)

All patients must be medically fit candidates for radical prostatectomy.

A patient with any retinopathy will only be enrolled into the study with the approval of a board-certified ophthalmologist

All patients must give informed consent indicating they are aware of the investigational nature of this study treatment prior to any study procedures being performed.

Exclusion Criteria

Patients may not have received radiation therapy for their prostate cancer.

Patients may not have received chemotherapy for their prostate cancer.

Patients with gastrointestinal abnormalities including: inability to take oral medication, requirement for intravenous alimentation, or prior major surgery or diseases which may cause malabsorption (e.g. bowel resection, ischemic bowel, Crohns or Ulcerative colitis)

A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment will be excluded.

Patients with significant cardiac disease: including uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous 3 months, or serious cardiac arrhythmias, including a QT interval corrected for heart rate using the Fridericia formula of ≥ 450 ms, or history of Torsade de pointes will be excluded.

Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol will be excluded.

Patients receiving any disease-modifying anti-rheumatic drugs (DMARDs) will be excluded.

Patients with known or a history of G6PD deficiency will be excluded. Eligible patients will be based on clinician-investigator assessment, that the patient is not at an increased risk for G6PD deficiency (assessment should include information regarding self-reported race/ancestry), OR the patient has a negative screening test for G6PD deficiency.

Patients taking other commercially available medications which may theoretically either stimulate or inhibit autophagy (calcitriol and chloroquine) will be excluded.

Patients chronically taking drugs known to cause torsades de pointes will be excluded unless those agents can be discontinued for a period \> 6 times their half-life before study enrollment

Patients with poorly controlled diabetes mellitus will be excluded.

Patients with a history of epilepsy will be excluded.

Patients with a history of porphyria will be excluded

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lebanon?

Yes, this clinical trial (NCT06408298) has an active research site in Lebanon, NH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Resectable Localized Prostate Cancer Treatment Options in Lebanon, NH

If you're searching for resectable localized prostate cancer treatment options in Lebanon, NH, this clinical trial (NCT06408298) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lebanon research site is actively enrolling participants for this clinical trial. You'll receive care from experienced resectable localized prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all resectable localized prostate cancer clinical trials near you to find additional studies recruiting in your area.

Resectable Localized Prostate Cancer Clinical Trial in Lebanon, NH

Expert Care in Lebanon

IRB Approved

No-Cost Care

Apply for This Lebanon Location

Why Participate?

Simple Process